In an AML CAR therapy targeting GRP78, Hebbar and colleagues demonstrated that using dastatinib during GRP78-CAR T-cell manufacturing blocked CAR signaling and GRP78 cell surface expression, improving efficacy in in vitro and mouse models [32]. Here, HSPA5 is linked to acute myeloid leukemia.